In this episode, Global Trac Solution’s CEO, David Flores, sits down with Dr. Hyder A. Khoja to learn more about the work they’re doing at Transcendent Therapeutics Inc.
Similar Posts
The Top 5 Psychedelics Podcasts
New psychedelic podcasts are popping up every week, but which ones are worth listening to? Here’s a few of our favorites.
Meet Bright Minds: The NEXT GEN Psychedelics Company Tackling Pain, Depression and MORE (DRUG/BMBIF)
In today’s episode of the Psychedelic Spotlight Podcast, James Hallifax from the Psychedelic Investor YouTube Channel interviews Ian McDonald, CEO of Bright Minds BioScience. For any investors out there, Bright Minds ticker symbol is DRUG on the Canadian CSE and BMBIF on the American OTC market.
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. Bright Minds is a company working on second and third generation psychedelics to treat a variety of ailments including depression, PTSD, epilepsy, addiction and more. The driving philosophy is that while classic psychedelics such as psilocybin and LSD do show great potential to be used in a therapy setting to treat mental health issues, the compounds also have limitations.
At Bright Minds, the goal is to engineer completely new compounds, often based on the structure of classical psychedelics, that keep the benefits of said drugs while doing away with potential negatives. Important to note is that while psychedelic derived drugs are a focus of the company, they also are creating non-psychedelic compounds for a variety of ailments, including different forms of addiction.
In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).
#BrightMinds #ThePsychedelicInvestor #PsychedelicStocks
Interview With Yaron Conforti, Novamind
In this episode, Psychedelic Spotlights, Director of Content, Jill Ettinger sits down with Chief Executive Officer, Director, and Co-Founder of Novamind, Yaron Conforti.
Interview With Daniel Carcillo, Natalie Ginsberg, Olivia Mannix & Klee Irwin
This week on the Psychedelic Spotlight podcast, we provide a recap of the inaugural Benzinga Psychedelic Capital Conference which took place in Fontainebleau Miami Beach on April 19, 2022.
MindMed gets FANTASTIC News from the FDA, Causing its Stock to Skyrocket (MNMD/MMED) | Project Lucy
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
MindMed (Nasdaq: MNMD, NEO: MMED) today announced that their Flagship Program, Project Lucy, has been given the green light from the FDA. MindMed is set to start a phase 2b Clinical Trial treating Generalized Anxiety Disorder with MM-102.
In response, MindMed’s stock has SKYROCKETED! It is up 39% at the time of writing and it could go higher. The psychedelic stock has been battered over the last 8 months, so it is good to see positive news affecting the price.
MindMed is a company attempting to treat mental health conditions such as Anxiety and Depression with Psychedelic Therapies.
Can psychedelics relieve anxiety and treat mental health? MindMed wants to know!
#MNMDstock# MindMed #Psychedelics
Health Canada’s Dealer’s Licence & Section 56 Explained with Benjamin Lightburn
Benjamin Lightburn of Filament Health discusses the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.